LifeVantage Revenue Drops 25% Amid GLP-1 System Decline
Event summary
- Revenue fell 25.2% YoY to $43.7M in Q3 FY2026, with Americas region down 28.9% due to MindBody GLP-1 System® sales decline.
- Net income per diluted share dropped to $0.11 from $0.26 YoY.
- Adjusted EBITDA halved to $3.2M from $6.4M YoY.
- Active accounts decreased by 22.1% YoY to 109,000.
- Company repurchased 250,000 shares for $1.6M in first nine months of FY2026.
The big picture
LifeVantage's sharp revenue decline highlights the challenges in the health and wellness sector, particularly with GLP-1 related products. The company's strategic focus on international expansion and new product launches, such as LoveBiome, will be critical in determining its ability to recover from this downturn. The direct selling model's sensitivity to economic conditions adds another layer of complexity to its turnaround efforts.
What we're watching
- Product Strategy
- Whether LoveBiome acquisition can offset MindBody GLP-1 System® sales decline.
- Market Expansion
- The pace at which international expansion can drive revenue growth.
- Cost Management
- How effectively LifeVantage can control expenses amid declining sales.
Related topics